gene_symbol
CD3E
hgnc_id
HGNC:1674
binding_type
antigen recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Linvoseltamab uses its anti-CD3 arm to engage and activate T cells; it does not kill CD3+ T cells. Activated T cells then kill BCMA-expressing tumor cells via perforin/granzyme after immune synapse formation.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
TCR–CD3 complex on T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05828511
disease_id_num_tar_ref
964
drug_id_num_tar_ref
2640